An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

• المؤلفون الرئيسيون: Josephina P. M. Vrouwe (مؤلف), Ingrid M. C. Kamerling (مؤلف), Michiel J. vanEsdonk (مؤلف), Josbert M. Metselaar (مؤلف), Frederik E. Stuurman (مؤلف), Gabri van derPluijm (مؤلف), Jacobus Burggraaf (مؤلف), Susanne Osanto (مؤلف)
• التنسيق: كتاب
• منشور في: Wiley, 2021-10-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...